Martin Williams MS, MBA, is an entrepreneurial executive and leader with over thirty years of global biopharmaceutical experience. He has achieved senior leadership positions in several multinational pharmaceutical companies, and public and private biotechnology companies. He has successfully closed over $4 billion in corporate transactions, including financings and strategic partnerships.
Prior to joining Caraway therapeutics, Mr. Williams was the President and CEO of Tokai Pharmaceuticals, an oncology company with a small molecule in Phase 2 for prostate cancer. He is also the Co-Founder and Chairman of Yuma Therapeutics, an early-stage biopharmaceutical company developing small molecule drugs for neurodegenerative conditions, such as Alzheimer’s disease. Earlier in his career, Mr. Williams served as chief business officer at Dicerna Pharmaceuticals, an RNA interference platform technology company, where he closed a $1.4 billion partnership with Kyowa Hakko Kirin. He was chief business officer at Synta Pharmaceuticals, a small molecule oncology and inflammatory company, where he completed the company’s IPO and closed a $1 billion collaboration with GlaxoSmithKline for its lead oncology product. He also has significant commercial experience having directed the development and commercialization of several blockbuster brands, including GSK’s Zantac and Zofran; Roche’s Xenical; and Wyeth’s (now Pfizer) Zosyn/Tazocin.
Mr. Williams has an M.B.A. from Harvard Business School, an M.S. from the University of Manchester, England and a B.A. in biology from the University of Humberside in Hull, England.